You are here

Article info

Article menu

Download PDFPDF

Hypothesis
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?

Authors

  • Winnie G Vos Department of Medical Biochemistry, University of Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Esther Lutgens Cardiovascular Medicine, Mayo Clinic, Rochester, New York, USAInstitute for Cardiovascular Prevention, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany PubMed articlesGoogle scholar articles
  • Tom T P Seijkens Medical Biochemistry, Amsterdam University Medical Centres, Duivendrecht, The NetherlandsMedical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Tom T P Seijkens; t.t.seijkens{at}amsterdamumc.nl
View Full Text

Citation

Vos WG, Lutgens E, Seijkens TTP
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
Journal for ImmunoTherapy of Cancer 2022;10:e005611. doi: 10.1136/jitc-2022-005611

Publication history

  • Accepted August 9, 2022
  • First published September 2, 2022.
Online issue publication 
March 12, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.